Vir Biotechnology Inc

Vir Biotechnology, Inc. (NASDAQ: VIR) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. 

Key Business and Financial Updates:

• Completion of the ECLIPSE Registrational Program for Chronic Hepatitis Delta: Vir Biotechnology, Inc. (NASDAQ: VIR) announced the successful initiation of all three trials in its ECLIPSE registrational program for chronic hepatitis delta (CHD), following the enrollment of the first participant in ECLIPSE 3. This Phase 2b study will compare the combination of tobevibart and elebsiran against bulevirtide in patients with CHD, aiming to generate pivotal data to support global market access and reimbursement. The full activation of the ECLIPSE program marks a critical step in advancing Vir’s mission to develop transformative therapies for CHD, a condition currently lacking approved treatments in the United States and with limited options worldwide.
• Advancing a Novel Combination Therapy for an Unmet Medical Need: The ECLIPSE trials build on the positive outcomes of the Phase 2 SOLSTICE study, which showed strong viral suppression with tobevibart and elebsiran. This dual-therapy approach is designed to interrupt multiple stages of the hepatitis delta virus lifecycle, offering the potential for improved efficacy and long-term patient adherence. CHD remains the most severe form of viral hepatitis, rapidly progressing to cirrhosis and liver failure; therefore, Vir’s combination therapy could redefine the standard of care. The program’s progress highlights Vir’s strategic focus on addressing high-burden diseases through scientific innovation and multi-mechanistic drug design.
• Regulatory Recognition and Global Development Momentum: The therapeutic promise of the tobevibart-elebsiran combination has been reinforced by multiple regulatory designations, including Breakthrough Therapy and Fast Track from the U.S. Food and Drug Administration and PRIME and orphan drug status from the European Medicines Agency. These designations reflect the urgency and global significance of advancing an effective CHD treatment. In addition to the ECLIPSE 3 study, the ongoing ECLIPSE 2 Phase 3 trial is enrolling patients who have not achieved undetectable HDV RNA levels on bulevirtide, further supporting global regulatory submissions. Together, these efforts underscore Vir’s accelerating progress toward developing a globally accessible, first-in-class therapy for CHD.
• Expansion into Oncology with VIR-5500 for Metastatic Prostate Cancer: Beyond hepatitis research, Vir Biotechnology announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for VIR-5500, an investigational PSMA-targeting PRO-XTEN® dual-masked T-cell engager, in combination with androgen receptor pathway inhibitors for metastatic castration-resistant prostate cancer (mCRPC). This expansion demonstrates Vir’s growing oncology focus and its commitment to leveraging the PRO-XTEN® platform to enhance precision and safety in immunotherapy. Early data from the monotherapy phase showed promising anti-tumor activity and safety, and the combination therapy aims to maximize clinical benefit in earlier lines of treatment. Collectively, these advancements position Vir Biotechnology as a multi-platform innovator addressing critical unmet needs across infectious diseases and oncology.

Technical Observation (on the daily chart):

• Trend Overview and Moving Averages Analysis: The daily chart of Vir Biotechnology, Inc. (VIR) indicates that the stock has been in a prolonged downtrend since late 2024, with consistent lower highs and lower lows. However, recent price action shows a mild recovery phase as the stock attempts to stabilize and move higher. The 50-day moving average (yellow line) currently stands around USD 5.04, while the 200-day moving average (blue line) is near USD 6.43. The price has recently risen above the 50-day average, suggesting the early signs of a potential trend reversal. A sustained move and close above the 200-day moving average would serve as a key technical confirmation of a medium-term bullish breakout, signaling renewed investor confidence after an extended consolidation period.
• Momentum Indicators and Market Strength: The Relative Strength Index (RSI 14) currently reads 68.00, indicating that the stock is exhibiting strong bullish momentum and nearing overbought levels. The RSI’s consistent movement above 60 over recent sessions reflects an improvement in market sentiment and growing buying pressure. The rising RSI trend aligns with the price’s move above short-term moving averages, signaling a shift from bearish to neutral-bullish sentiment. However, caution is warranted as further price acceleration without consolidation could push the RSI into overbought territory, increasing the likelihood of a short-term correction.
• Technical Outlook and Key Levels: From a broader technical perspective, VIR faces immediate resistance near USD 6.40–6.50, which coincides with the 200-day moving average—a decisive zone that will determine the sustainability of the ongoing uptrend. A breakout above this level could open the door to further gains toward USD 7.50–8.00, while strong support is established around USD 5.00, aligning with the 50-day moving average, and lower support at USD 4.20. A close below these support zones may indicate renewed downside pressure. Overall, the technical setup suggests that VIR is in an early recovery phase, backed by improving momentum and strengthening sentiment. Maintaining price action above USD 5.00 while consolidating below key resistance levels could pave the way for a gradual bullish continuation if accompanied by increased trading volumes.  

Vir Biotechnology, Inc. (NASDAQ: VIR) is demonstrating positive scientific, strategic, and technical momentum, positioning itself as a strong mid-cap biotechnology contender. The company has fully launched its ECLIPSE registrational program for chronic hepatitis delta, progressing three major clinical trials designed to bring forward a first-in-class therapy for one of the most severe liver diseases. Backed by encouraging data from its SOLSTICE Phase 2 study, Vir’s dual-therapy of tobevibart and elebsiran has shown strong viral suppression, earning Breakthrough Therapy, Fast Track, PRIME, and orphan drug designations from major global regulators—underscoring its medical and commercial potential. Additionally, the company is expanding into oncology with promising developments in VIR-5500, a novel PSMA-targeting therapy for metastatic prostate cancer, showing early signs of efficacy and safety. On the technical front, VIR’s stock has shown renewed bullish momentum, trading above its 50-day moving average with the RSI at 68, signaling strengthening investor sentiment and the potential for a medium-term bullish breakout if it surpasses resistance near USD 6.50. Overall, Vir Biotechnology’s advancing clinical pipeline, regulatory recognition, and improving technical setup highlight a strong phase of growth and recovery potential.

As per the above-mentioned price action, important support near USD 5.00-USD 5.50, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given for Vir Biotechnology, Inc. (NASDAQ: VIR) at the closing price of USD 6.04, as of October 09, 2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is October 09, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.